Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active | |||
| Remsima | infliximab | Crohn’s disease | Active | |||
| Remsima | infliximab | Ulcerative Colitis | Active | |||
| Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Active | |||
| Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active | |||
| Epidiolex | cannabidiol | Dravet Syndrome (DS) | Active | |||
| Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Active | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
| Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Active |
Last Updated : April 29, 2024